H.R. 10336 aims to amend the Federal Food, Drug, and Cosmetic Act to enhance the regulatory framework surrounding dietary supplements. The bill seeks to encourage innovation in the dietary supplement industry and improve consumer access to these products by clarifying how dietary supplements are regulated in relation to drugs, specifically addressing issues of drug preclusion.
H.R. 10336 was introduced in the 119th Congress by Diana Harshbarger (Republican) and is currently listed as “Introduced”. It is classified under the Health policy area, one of 508 bills in that area we track this Congress.
Diana Harshbarger is the sponsor of 11 bills in our database this Congress, so H.R. 10336 is part of a broader legislative agenda rather than a one-off proposal.
Our conflict-of-interest analysis rates H.R. 10336 2/10 (low risk), higher than 76% of analyzed bills; the average in Health is 3.9/10.
Supporters of H.R. 10336 argue that the bill will foster innovation in the dietary supplement industry, potentially leading to new products that can benefit consumers. They emphasize that by clarifying regulations, the bill would make it easier for companies to bring safe and effective dietary supplements to market, ultimately increasing consumer choices and access to health products.
Critics of H.R. 10336 express concerns that the bill may weaken consumer protections by allowing more dietary supplements to enter the market without rigorous safety and efficacy standards. They worry that the regulatory changes could lead to an increase in untested or potentially harmful products being available to consumers, undermining public health and safety.
The analysis of H.R. 10336, sponsored by Diana Harshbarger, reveals no direct industry overlaps between the bill's subject matter and the sponsor's top donor industries. This indicates a low risk of conflicts of interest as the bill aims to amend the Federal Food, Drug, and Cosmetic Act concerning dietary supplements, while the sponsor's donors do not represent industries directly involved in dietary supplement regulation or production. Without significant financial ties to the dietary supplement industry, the potential for undue influence appears minimal. Voters should be aware that while the absence of overlaps suggests a lower risk, it is still essential to monitor any indirect connections that may arise in the future.
Top industries funding Diana Harshbarger, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
What does H.R. 10336 do?
H.R. 10336 aims to amend the Federal Food, Drug, and Cosmetic Act to enhance the regulatory framework surrounding dietary supplements. The bill seeks to encourage innovation in the dietary supplement industry and improve consumer access to these products by clarifying how dietary supplements are regulated in relation to drugs, specifically addressing issues of drug preclusion.
Has H.R. 10336 received a floor vote?
No roll-call vote on H.R. 10336 is recorded in our database yet. Its current status is “Introduced”.
Does H.R. 10336 have a conflict of interest?
Our conflict-of-interest analysis rates H.R. 10336 2/10 (low risk), higher than 76% of analyzed bills; the average in Health is 3.9/10. This score reflects overlap between the sponsor’s campaign funding, lobbying activity, and the industries the bill affects. It is a transparency indicator, not an accusation.
What is the status of H.R. 10336?
H.R. 10336 is currently “Introduced” as of our last update on September 15, 2026.
Who sponsored H.R. 10336?
H.R. 10336 was sponsored by Diana Harshbarger (Republican).
